Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR441566 dose-ranging study in adults with moderate to severe plaque psoriasis
2023-503911-14-00Phase 2Completed
- Sponsor
- Sanofi
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis comparing SAR441566 with Placebo (2 arms). Primary endpoint: PASI75 at week 12. Started Dec 2023; status: completed.
02
Drugs
balinatunfib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2023-503911-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503911-14-00.